Proceedings From the First International Workshop at Sidra Medicine: “Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development”, 15th–16th February 2019, Doha, Qatar
Year: 2021
Type: article
Abstract: The progress in the isolation and characterization of tumor antigen (TA)-specific T lymphocytes and in the genetic modification of immune cells allowed the clinical development of adoptive cell therapy (ACT). Several clinical studies highlighted the striking clinical activity of T cells engineered to express either Chimeric Antigen (CAR) or T Cell (TCR) Receptors to target molecularly defined antigens expressed on tumor cells. The breakthrough of immunotherapy is represented by the approval of CAR-T cells specific for advanced or refractory CD19+ B cell malignancies by both the Food and Drug Administration (FDA) and the European Medicinal Agency (EMA). Moreover, advances in the manufacturing and gene editing of engineered immune cells contributed to the selection of drug products with desired phenotype, refined specificity and decreased toxicity. An important step toward the optimization of CAR-T cell therapy is the development of “off-the shelf” T cell products that allow to reduce the complexity and the costs of the manufacturing and to render these drugs available for a broad number of cancer patients. The Engineered Immune Cells in Cancer Immunotherapy (EICCI) workshop hosted in Doha, Qatar, renowned experts, from both academia and industry, to present and discuss the progress on both pre-clinical and clinical development of genetically modified immune cells, including advances in the “off-the-shelf” manufacturing. These experts have addressed also organizational needs and hurdles for the clinical grade production and application of these biological drugs.
Source: Frontiers in Immunology
Authors: Bella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, Dhanya Kizhakayil, Chiara Bonini, Reuben Benjamin, Renier Brentjens, Christian J. Buchholz, Giulia Casorati, Soldano Ferrone, Frederick L. Locke, Francisco Martin, Axel Schambach, Cameron Turtle, Paul Veys, Hans J. van der Vliet, Cristina Maccalli
Institutions: Sidra Medical and Research Center, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, King's College Hospital, Memorial Sloan Kettering Cancer Center, Paul Ehrlich Institut, Harvard University, Massachusetts General Hospital, Moffitt Cancer Center, Universidad de Granada, Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research, Boston Children's Hospital, Medizinische Hochschule Hannover, Fred Hutch Cancer Center, Great Ormond Street Hospital, University College London, Lava Therapeutics (Netherlands), Amsterdam University Medical Centers, Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,950
Award: Cancer Center Support Grant
OpenAlex ID: W3119649935